nobody should copy my schedule, im describing it because people asked what a slow ramp looks like
#cagrilintide 2026-03-02
Monday22 messages4 participantstimes are UTC
Highlights from this day
- dexa_or_bia — anyone got two Medutest results on the same QYB lot for this 16:21
- baseline_drift — how do people separate which of the two is doing what in a combination combination GI was worse than either alone for me, which is not what i had read anywhere 18:14
- endotoxin_ed — ok so monotherapy was underwhelming for me and i say that as someone who wanted it to work, someone check my working 18:46
- endotoxin_ed — anyone dosing this on a different day to their tirzepatide 18:48
anyone got two Medutest results on the same QYB lot for this
stopped for 18 months and the fullness went within a fortnight of the last dose
REDEFINE is the phase 3 programme, most of what gets quoted casually in here is earlier work
is 2.4 the number for this too or am i confusing compounds
is there a reason people titrate this over more weeks than the others
[edited]separate days
how many weeks before you noticed anything on monotherapy
amylin not glp-1
monotherapy question, did appetite move for you without a GLP-1 alongside
*PeptideMeter not the other one
the reason nausea reads differently is timing, mine arrived on the second day rather than the first
[edited]did anyone add this to an existing retatrutide dose rather than starting both
is the nausea profile genuinely different or am i imagining it
the numbers everyone quotes come from the combination, so comparing them to monotherapy logs is unfair
thats the phase 3 one
how do people separate which of the two is doing what in a combination
combination GI was worse than either alone for me, which is not what i had read anywhere
monotherapy here
ok so monotherapy was underwhelming for me and i say that as someone who wanted it to work, someone check my working
anyone dosing this on a different day to their tirzepatide
📈4😂1👀6
added it to an existing cagrilintide dose rather than starting both, which made attribution possible